Category Archives: Press Release

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Jul 10, 2023, 16:15 ET -Statistically significant improvements in IGA (Investigator Global Assessment) and EASI (Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body…

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial NEWS PROVIDED BY Alphyn Biologics May 04, 2023, 07:30 ET Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target…

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress NEWS PROVIDED BY Alphyn Biologics Apr 27, 2023, 07:30 ET ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase…

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Jan 4, 2023, 07:30 ET ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase…

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…